Iovance (IOVA) news
Recent news
Iovance Biotherapeutics Inc: Baird raises target price to $11 from $6
Baird analyst Collen Kusy recently raised Iovance's price target to $11 from $6, while maintaining a Neutral rating on the stock. This adjustment reflects updated modeling assumptions and recent developments in the company’s financial and operational performance. Iovance, a commercial-stage…
AInvest Wire · 7d agoIovance Biotherapeutics appoints Noah Berkowitz, M.D., Ph.D., as chief medical officer
AInvest Wire · Oct 1, 2026Iovance Biotherapeutics: Wells Fargo raises target price to $18 from $14
AInvest Wire · Sep 30, 2026IOVance Biotherapeutics Inc: TD Cowen raises target price to $16 from $10
TD Cowen has revised its price target for IOVance Biotherapeutics Inc (NASDAQ: IOVA), raising it from $10 to $16 , reflecting a more optimistic outlook for the biotechnology company. The adjustment follows a reassessment of the company’s clinical progress and market potential. IOVance, which…
AInvest Wire · Sep 29, 2026IOVance Biotherapeutics, Inc.: H.C. Wainwright raises target price to $20 from $9
HC Wainwright & Co. has revised its price target for Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), raising it to $20 from $9, while maintaining a Buy rating. This adjustment follows recent presentations at the H.C. Wainwright and Wells Fargo conferences, which highlighted key clinical pipeline…
AInvest Wire · Sep 29, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.